EDITORIAL COMMENT

Pleiotropic Effects of Statins

Acutely Good, But Chronically Bad?*

Rainer Schulz, MD, PhD†
Essen, Germany

Inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase (statins) are powerful lipid-lowering drugs that have been proven effective in primary and secondary prevention of coronary artery disease (1). However, ongoing discussion persists on whether or not statins exert clinically relevant protection from cardiovascular disease independent of their lipid-lowering action (2,3), the so-called pleiotropic effects. The pleiotropic effects of statins are related to the reduced formation of isoprenoids, which are responsible for post-translational modification of proteins (for review, see Werner et al. [4]). Among those proteins, the reduced prenylation and thus activity of small G-proteins (Ras, Rho) appears to be of major importance.

The small G-protein RhoA is involved in myocardial ischemia/reperfusion injury; its pharmacologic blockade reduces infarct size in mice after 30 min of coronary artery occlusion and 24 h of reperfusion (5). RhoA inhibits the activity of protein kinase B (PKB/Akt), an enzyme that, together with the phosphatidylinositol-3 kinase (PI3K), is important for triggering the cardioprotection achieved by ischemic preconditioning (6,7) and for mediating the reduction of ischemia/reperfusion injury after treatment with bradykinin (8), insulin, insulin-like growth factor-1, or urocortin (for review, see Hausenloy and Yellon [9]) (Fig. 1). Downstream of PI3K and Akt, endothelial nitric oxide synthase 3 (NOS3) activation, mitochondrial adenosine triphosphate (ATP)-dependent potassium channel activation, and mitochondrial permeability transition pore inhibition all are involved in mediating the resulting cardioprotective effect (9).

Statins can activate the PI3K/Akt pathway directly by increased translocation of Akt to the sarcolemmal membrane (10) or indirectly by a reduced RhoA activity; RhoA inhibits PKB/Akt activity (11).

In agreement with its effect on PI3K/Akt, statins reduce infarct size after ischemia/reperfusion in mouse (12–15), rat (16–19), dog (20), and pig (21) hearts in vitro (14,16) or in vivo (12,13,15,17–19,21–23). Infarct size reduction by statins is dose-dependent and effective when statin treatment is initiated within three days before ischemia or even when started just before reperfusion (14,19). Blockade of PI3K (14,19,20), NOS3 (13,14,18,19,22), or ATP-dependent potassium channels (23) abolishes the cardioprotective effect of statins. Increased survival after hypoxia/reoxygenation by statin treatment also has been observed in isolated human cardiomyocytes (24), indicating that interaction of different cell types is not required for the cardioprotection to be obtained.

So far, only a single study in rabbits failed to demonstrate an infarct size reduction by statin treatment; in this study, rabbits fed a cholesterol-rich diet for 16 weeks received pravastatin (5 mg/kg/day) for 8 weeks before the initiation of 30 min ischemia followed by reperfusion. Pravastatin had no significant effect on cholesterol levels, but it restored the cardioprotection achieved by ischemic preconditioning, which was otherwise lost in hearts from hypercholesterolemic rabbits (25). This finding suggests that the more acute/subacute direct cardioprotective effect of statins by modulating protein kinase activity is lost over longer treatment periods but that the potential to potentiate the cardioprotection achieved by other stimuli remains.

In line with this idea, the study by Mensah et al. (26) in this issue of the Journal also clearly demonstrates that atorvastatin (20 mg/kg/day), although reducing infarct size when given for less than three days before ischemia/reperfusion, lost its cardioprotective effect when administered for one or two weeks before ischemia/reperfusion. The authors are the first to associate this finding with an up-regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10), a protein phosphatase known to inhibit the function of PI3K (27). The expression of PTEN is controlled by peroxisome proliferator-activated receptor gamma and—at least in monocytes—peroxisome proliferator-activated receptor gamma activity is increased with chronic statin treatment (28). As a result, although acute/subacute statin treatment might increase PKB/Akt activity, chronic statin treatment might counteract PKB/Akt activation by increasing PTEN expression. Unfortunately, neither PI3K nor PKB/Akt nor NOS3 phosphorylation were assessed in the present study. Also of great importance, however, is that acute treatment with 40 mg/kg atorvastatin 3 to 4 h before ischemia on top of the chronic treatment restored the reduction in infarct size, suggesting that the inhibition of PI3K activity and subsequently PKB/Akt activity during chronic statin treatment can be overcome by acutely increasing PKB/Akt phosphorylation; such increased PKB/Akt phosphorylation occurs acutely after statin administration. However, to further prove this idea, studies with measurements of PI3K, PKB/Akt, and endothelial nitric oxide synthase phosphorylation during acute statin treatment on top of chronic therapy are required.

Do all statins act the same? Although an ongoing discussion persists on whether or not all statins behave...
similar concerning cardiovascular risk reduction and pleiotropic effects (29), all available statins (atorvastatin, cerivastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin), when given before ischemia/reperfusion, reduce infarct size in animal experiments. Differences might exist regarding the minimal duration between drug administration and initiation of ischemia as well as the required drug concentration, reflecting the different pharmacologic profiles of the drugs.

Is there any evidence that statins reduce the extent of infarction clinically? Plaque rupture occurring either spontaneously or during coronary interventions causes microinfarction secondary to coronary microembolization (for review, see Erbel and Heusch [30] and Heusch et al. [31]). The extent of microinfarction—as indicated by an increase in creatine kinase-myocardial band and troponin I—after coronary interventions is reduced in patients under statin treatment (32). Although during long-term statin treatment the plaque volume is reduced (33), thereby reducing the extent of coronary microembolization, reduced microinfarction is observed even when statin treatment is started just three (34) to seven days (35) before coronary interventions. Thus, statins have clearly some acute cholesterol-independent cardioprotective effects that, however, might be lost during chronic use. Nevertheless, during chronic statin treatment, lowering of the lipid load is cardioprotective. Future clinical studies will have to elucidate whether or not the combination of an acute statin treatment on top of its chronic use exerts any benefit for the patient.

**REFERENCES**


29. Ready T. Despite hype, not all statins are the same, experts say. Nat Med 2004;10:442.


